10-Q: Protagenic Therapeutics Reports Q2 Loss, Restructures

Protagenic Therapeutics reported a significant increase in net loss for Q2 2026, implemented a major restructuring plan, and faces ongoing Nasdaq compliance issues despite a recent reverse merger.

Summary

• Protagenic Therapeutics, Inc. (PTIX) reported a net loss of $(5,927,019) for the six months ended September 30, 2025, a substantial increase from $(906,742) for the same period in 2024.
• The company completed a reverse merger with Phytanix Bio, Inc. on May 15, 2025, with Phytanix Bio being the accounting acquirer, leading to a change in fiscal year end to March 31.
• A focused restructuring plan was approved on August 8, 2025, to transition to a virtual operating model, concentrate capital on the lead clinical program (PT00114), and temporarily suspend preclinical programs.
• The restructuring is expected to reduce annualized operating expenses by approximately $8 million.
• Cash in bank increased significantly to $2,722,451 as of September 30, 2025, from $14,531 as of March 31, 2025, primarily due to $4.3 million raised from warrant exercises and a capital raise.
• Working capital deficit worsened to $(6,845,200) as of September 30, 2025, from $(4,952,959) as of March 31, 2025.
• The company acquired five preclinical drug candidate assets (PHYX-001, PHYX-002, PHYX-003, PHYX-004, PHYX-005) and associated intellectual property through the merger.
• Protagenic Therapeutics received a Nasdaq delisting notice on August 20, 2025, for failing to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• The company previously regained Nasdaq compliance for minimum bid price and equity requirements in June 2025 after a 1-for-14 reverse stock split on May 5, 2025, but is under a one-year Mandatory Panel Monitor.
• Identified material weaknesses in internal control over financial reporting include insufficient segregation of duties and limited multiple reviews in financial statement preparation.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a substantial net loss, worsening working capital deficit, and going concern doubts. While the reverse merger expanded the pipeline and a restructuring plan aims to cut costs, ongoing Nasdaq compliance issues and a legal dispute over the merger itself introduce considerable uncertainty and risk. The positive cash increase is offset by the underlying operational losses and the need for further capital.

Positives

• Cash in bank increased significantly to $2,722,451 as of September 30, 2025, from $14,531 as of March 31, 2025, providing a stronger liquidity position in the short term.
• The company successfully raised approximately $4.3 million from warrant exercises and a capital raise during the six months ended September 30, 2025.
• The reverse merger with Phytanix Bio, Inc. expanded the product pipeline with five preclinical drug candidate assets and associated intellectual property across multiple therapeutic areas.
• The restructuring plan is expected to reduce annualized operating expenses by approximately $8 million, aiming for a more disciplined cost structure and focus on high-priority clinical programs.
• Regained compliance with several Nasdaq listing rules (Bid Price, Public Float, Equity, Annual Shareholder Meeting Rule) in June 2025, although subject to a one-year monitoring period.

Negatives

• Net loss for the six months ended September 30, 2025, increased significantly to $(5,927,019) compared to $(906,742) for the same period in 2024.
• Working capital deficit worsened to $(6,845,200) as of September 30, 2025, from $(4,952,959) as of March 31, 2025.
• Accumulated deficit increased to $(11,324,625) as of September 30, 2025, indicating continued operational losses.
• Total liabilities increased substantially to $9,703,412 as of September 30, 2025, from $5,042,052 as of March 31, 2025, partly due to increased derivative liabilities.
• Received another Nasdaq delisting notice on August 20, 2025, for failure to timely file the Quarterly Report on Form 10-Q, indicating ongoing compliance challenges.
• The company is not forecasting recovery of any funds from Axiom Real-Time Metrics Inc., despite a legal claim for at least $643,253, due to Axiom's receivership.
• The company filed a Verified Complaint on October 28, 2025, seeking rescission of the Share Exchange Agreement with Phytanix Bio, Inc. or damages, indicating potential issues with the recent merger.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to significant recurring losses, accumulated deficit, and negative cash flows from operations.
• The company will need to obtain debt or equity financing by the end of fiscal year March 31, 2026, to fund operations beyond Q2 FY 2027 (September 30, 2026), with no committed sources of additional capital.
• Ongoing Nasdaq listing compliance issues, including a recent delisting notice for late filing and a one-year Mandatory Panel Monitor, pose a risk of delisting.
• The company faces risks associated with early-stage drug development, as all five acquired preclinical assets remain at the preclinical stage.
• Material weaknesses in internal control over financial reporting, specifically insufficient segregation of duties and limited multiple reviews, could lead to material misstatements.
• The legal dispute seeking rescission of the Phytanix Bio merger or damages introduces uncertainty regarding the company's structure and financial position.
• The company is not expected to recover funds from Axiom Real-Time Metrics Inc. due to its receivership, resulting in a potential loss of at least $643,253.

Future Outlook

The company anticipates continued significant expenses and losses for the foreseeable future, with no revenue from product sales expected before 2027. Cash resources are projected to fund operations until approximately the end of Q2 FY 2027 (September 30, 2026), requiring additional capital raises or partnership agreements to continue beyond this period. The company plans to focus on completing the Phase I study for PT00114 and initiating a Phase IIa study by Q4 FY2026, while seeking external funding for its paused preclinical programs.

Management Comments

• Management believes that a disciplined cost structure and a sharper focus on near-term value inflection are in the best interests of the Company and its stockholders, as evidenced by the restructuring plan.
• Management does not know whether additional financing will be on terms favorable or acceptable when needed, if at all, and may need to curtail development efforts if funds are not available.
• Management believes that the disclosures in these unaudited consolidated financial statements are adequate to make the information presented not misleading.

Industry Context

Protagenic Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on neuropsychiatric and mood disorders, epilepsy, obesity, bladder pain, and CNS/inflammatory conditions. The acquisition of Phytanix Bio's pipeline, including cannabinoid-based and novel molecules, positions the company in areas with significant unmet medical needs and large market potential, such as obesity (competing with blockbuster therapies like tirzepatide and semaglutide). However, the company is in the early preclinical and Phase I development stages, facing high risks and long timelines typical of the industry, particularly for FDA approval and commercialization.

Comparison to Industry Standards

• PHYX-001, a Kv7.2/7.3 agonist, shares the same mechanism of action as compounds like BVH-7000 and XEN1101, which are currently in Phase 3 clinical trials for focal onset seizures (FOS), generalized tonic-clonic seizures (GTCS), and major depressive disorder (MDD. XEN1101 (Azetukalner) has shown encouraging efficacy and safety in Phase 2 studies (French et al., 2023).
• PHYX-002 aims to develop a cannabinoid product with improved potency and lower dosing requirements compared to currently available cannabinoid medicines, including Epidiolex.
• PHYX-003 is designed to potentially enhance weight-loss outcomes compared with current blockbuster therapies such as tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy), addressing the rapid growth and high unmet need in the global obesity market.
• PHYX-004 targets bladder pain syndrome / interstitial cystitis, an indication with significant unmet medical need due to limitations of the current standard of care, Elmiron.

Management Changes

Corporate Governance

Legal Proceedings

• Filed a complaint against Axiom Real-Time Metrics Inc. on May 27, 2025, seeking at least $643,253 for pre-paid clinical study work that Axiom failed to undertake.
• Axiom Real-Time Metrics Inc. was placed into receivership on July 11, 2025, and its assets were sold, leading the company to not forecast recovering any funds from Axiom.
• Filed a Verified Complaint in the Court of Chancery of the State of Delaware on October 28, 2025, seeking rescission of the Share Exchange Agreement with Phytanix Bio, Inc. or, in the alternative, damages and an order compelling delivery of audited financial statements.

Related Party Transactions

• Leases office space from a company in which an officer has an interest for $2,500 per month, believed to be at or below market rate.
• An officer provides free office space (conference room) for board and shareholder meetings.
• Related parties made advances to the company totaling $62,347 during the six months ended September 30, 2025.
• The company owed related parties $841,548 as of September 30, 2025, for non-interest bearing advances with no specified repayment terms.
• The Board approved the forgiveness of an intercompany loan owed by ABTI Pharma Limited to the company, in the amount of £317,480.40 GBP ($410,756 USD), effective March 31, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and potential negative impact on share price due to ongoing losses, Nasdaq compliance issues, and legal disputes.
• Employees (including former CEO and COO) have been impacted by the restructuring plan, which involved workforce reductions and changes in management roles.
• Creditors, particularly those holding notes payable and related party loans, face uncertainty given the company's going concern doubts and accumulated deficit.
• Partners and potential partners for preclinical programs may be impacted by the company's decision to pause these programs and seek external funding or out-licensing.

Next Steps

• Submit a plan to Nasdaq to regain compliance for the late filing of the Form 10-Q within 60 calendar days from August 20, 2025.
• Implement enhanced controls and procedures to address material weaknesses in internal control over financial reporting, including segregation of duties.
• Complete the multiple dose portion of the Phase I study for PT00114 and make results publicly available (anticipated Q2 FY 2026, ending September 30, 2025).
• Initiate the Phase IIa study for PT00114 (anticipated Q4 FY2026, ending March 31, 2026).
• Evaluate strategic alternatives, including partnerships and/or out-licensing, for the temporarily suspended preclinical programs (PHYX-001 to PHYX-005).
• Obtain debt or equity financing by the end of fiscal year March 31, 2026, to fund operations beyond Q2 FY 2027 (September 30, 2026).
• Continue legal proceedings seeking rescission of the Share Exchange Agreement with Phytanix Bio, Inc. or damages.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss, worsening working capital deficit, and explicit 'going concern' doubts. While a recent capital raise provided temporary liquidity, the company projects needing more financing by March 2026 to operate beyond September 2026, with no committed sources. The restructuring plan, while aiming for cost reduction, involves pausing preclinical programs, which could delay future value creation. Critically, the company received another Nasdaq delisting notice for late filing, indicating persistent operational and governance issues. Furthermore, the legal action seeking to rescind the recent reverse merger introduces significant uncertainty about the company's core assets and strategic direction. The inability to recover funds from Axiom adds to the financial strain. These factors collectively point to a highly speculative investment with substantial downside risk, making a 'sell' recommendation appropriate for seasoned investors.

Keywords

Biopharmaceutical, Neuropsychiatric disorders, Drug development, SEC filing, 10-Q, Reverse merger, Restructuring, Nasdaq compliance, Going concern, Clinical trials, Preclinical assets, Intellectual property, Cannabinoid therapeutics, Obesity drug, Epilepsy treatment, Bladder pain syndrome, Stilbenoid program